相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor
S. Fourati et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
Miguel Malespin et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Response-Guided Duration of Direct Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
Alessio Aghemo et al.
GASTROENTEROLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
No one size fits allShortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection
O. El Sherif et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations
Pranesh Padmanabhan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
REPLY TO PADMANABHAN AND DIXIT: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments
Hirofumi Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
Yoshiki Koizumi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein
Hangfei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
Thi Huyen Tram Nguyen et al.
SCIENTIFIC REPORTS (2017)
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents
Ashish Goyal et al.
ANTIVIRAL RESEARCH (2017)
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2016)
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens
Benjamin Maasoumy et al.
JOURNAL OF HEPATOLOGY (2016)
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Harel Dahari et al.
JOURNAL OF HEPATOLOGY (2016)
Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling
Abigail Jarret et al.
NATURE MEDICINE (2016)
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
Matthias Gotte et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway
Wei-Liang Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
George Lau et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes
Fuat Kurbanov et al.
ANTIVIRAL THERAPY (2015)
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Erik Lontok et al.
HEPATOLOGY (2015)
ON-TREATMENT VIRAL KINETICS DO NOT PREDICT SVR IN PATIENTS WITH ADVANCED LIVER DISEASE RECEIVING SOFOSBUVIR IN COMBINATION WITH DACLATASVIR OR SIMEPREVIR FOR 12 WEEKS
C. Hezode et al.
JOURNAL OF HEPATOLOGY (2015)
A signature for immune response correlates with HCV treatment outcome in Caucasian subjects
Brian J. Hare et al.
JOURNAL OF PROTEOMICS (2015)
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
Anita Kohli et al.
LANCET (2015)
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A
Jin-Hua Sun et al.
NATURE (2015)
Modelling hepatitis C therapy-predicting effects of treatment
Alan S. Perelson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Asma Ahmed et al.
VIRUSES-BASEL (2015)
Successes and Challenges on the Road to Cure Hepatitis C
Stacy M. Horner et al.
PLOS PATHOGENS (2015)
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
Fei Xiao et al.
GUT (2015)
Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin
Eisuke Murakami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling
Libin Rong et al.
ANTIVIRAL THERAPY (2014)
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
Yaron Rotman et al.
GUT (2014)
Simultaneous Detection of Hepatitis C Virus and Interferon Stimulated Gene Expression in Infected Human Liver
Stefan Wieland et al.
HEPATOLOGY (2014)
Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment
Pranesh Padmanabhan et al.
NATURE COMMUNICATIONS (2014)
Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
Eric L. Haseltine et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity
Hangfei Qi et al.
PLOS PATHOGENS (2014)
Use of Laser Capture Microdissection to Map Hepatitis C Virus-Positive Hepatocytes in Human Liver
Abraham J. Kandathil et al.
GASTROENTEROLOGY (2013)
Innate immunity and HCV
Markus H. Heim
JOURNAL OF HEPATOLOGY (2013)
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
Celia Perales et al.
JOURNAL OF VIROLOGY (2013)
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Jeremie Guedj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle
Marco Binder et al.
PLOS PATHOGENS (2013)
Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor
Libin Rong et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2012)
Identification of Type I and Type II Interferon-Induced Effectors Controlling Hepatitis C Virus Replication
Philippe Metz et al.
HEPATOLOGY (2012)
Characterization of Telaprevir Treatment Outcomes and Resistance in Patients With Prior Treatment Failure: Results From the REALIZE Trial
Sandra De Meyer et al.
HEPATOLOGY (2012)
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome
Daniel I. S. Rosenbloom et al.
NATURE MEDICINE (2012)
Genetics of IL28B and HCV-response to infection and treatment
C. Nelson Hayes et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
Bambang S. Adiwijaya et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
Ruy M. Ribeiro et al.
PLOS PATHOGENS (2012)
Failure of innate and adaptive immune responses in controlling hepatitis C virus infection
Robert Thimme et al.
FEMS MICROBIOLOGY REVIEWS (2012)
Multiple Ascending Dose Study of BMS-790052, a Nonstructural Protein 5A Replication Complex Inhibitor, in Patients Infected with Hepatitis C Virus Genotype 1
Richard E. Nettles et al.
HEPATOLOGY (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins et al.
NATURE (2011)
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
Megan H. Powdrill et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry
Pranesh Padmanabhan et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
E. Snoeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir
Fumitaka Suzuki et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
Bambang S. Adiwijaya et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation
Urtzi Garaigorta et al.
CELL HOST & MICROBE (2009)
A methodology for performing global uncertainty and sensitivity analysis in systems biology
Simeone Marino et al.
JOURNAL OF THEORETICAL BIOLOGY (2008)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C
Akiko Makiyama et al.
HEPATOLOGY RESEARCH (2006)
Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States
Omana V. Nainan et al.
GASTROENTEROLOGY (2006)
The interferon response circuit: Induction and suppression by pathogenic viruses
O Haller et al.
VIROLOGY (2006)
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies
JM Micallef et al.
JOURNAL OF VIRAL HEPATITIS (2006)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci et al.
JOURNAL OF HEPATOLOGY (2005)
Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
A Tsubota et al.
JOURNAL OF MEDICAL VIROLOGY (2005)
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
NM Dixit et al.
NATURE (2004)
分享论文
